 |
| May
1, 2026 |
| Regional
intelligence on Drugs, Diagnostics,
Devices & Digital Health |
|
|
|
* may need subscription to view |
 |
 |
| Boston's
most flexible contract vivarium
lab space: Start with a few study
cages and grow. |
|
Learn More
→ |
|
|
- Bambusa Therapeutics: Completes Patient
Enrollment in the Phase 1b/2a Trial Evaluating
BBT001 as a Treatment for Atopic Dermatitis More
- Cue Biopharma: Expands Pipeline With
Exclusive License From Ascendant Health
Sciences Ltd. for Clinical-Stage
Dual-Mechanism Anti-IgE Antibody More
- Cue Biopharma: Names Shao-Lee Lin M.D.,
Ph.D., CEO, President and Board Director to
Lead Continued Growth and Transformation
Into a Clinical-Stage Company More
- Dana-Farber: Experts Offer Perspective on
Link Between Pesticide Exposure and
Early-Onset Colorectal Cancer More
- MapLight Therapeutics: Completion of
Enrollment in ZEPHYR Phase 2 Trial and Updates
Expected Timing of Topline Results More
- Ora: Breakthrough Research in Ophthalmic
Clinical Trials, New Blind Canvas Project
Stories at ARVO 2026 More
- Rhythm Pharmaceuticals: IMCIVREE
(Setmelanotide) Granted Marketing
Authorization by European Commission for the
Treatment of Obesity and Control of Hunger in
Patients With Acquired Hypothalamic Obesity More
- Stealth BioTherapeutics: Commercial Launch
Update and Pipeline Progress Across
Mitochondrial Disease Portfolio More
|
|
 |
Charles
River CFO
Keeping It Steady During a
Company-Defining Moment |
|
Learn More
→ |
|
|
- Ardelyx: First Quarter 2026 Financial
Results and Business Update More
- Cue Biopharma: $30 Million Private Placement
More
- Damora Therapeutics: Inducement Grants Under
Nasdaq Listing Rule 5635(c)(4) More
- Ernexa Therapeutics: 1-for-25 Reverse Stock
Split More
- Hemab Therapeutics: Pricing of Upsized
Initial Public Offering More
More*
More*
- LSN: Hot Investor Mandates (Updated 4/28) More
- Massachusetts Biotech CEO Compensation
Climbs As Most Packages Rise in 2025 More*
- Moderna: First Quarter 2026 Financial
Results and Provides Business Updates More
- More on Avalyn Pharma Raising $300M in
IPO, Shares Surging 64% on First Day of
Trading More*
More*
More*
More
- More on PureTech Wanting to Get Its
Hub-and-Spoke Model Spinning Faster More*
- Revvity: Board Declares Quarterly Dividend More
- Seaport Therapeutics: Pricing of Upsized
Initial Public Offering More
More*
More*
- Syndax: First Quarter 2026 Financial Results
and Business Update More
|
|
|
 |
Pace®
Life Sciences
The CDMO That Takes You Further.
Your partner for Product
Development, Manufacturing,
Analytical Testing, Regulatory
Consulting & Operational
Support. |
|
Learn More
→ |
|
|
- BioPharmGuy News: Triple Dystopia,
F.I.E.R.C.E. Values, Beauty of Optics, Oatmeal
Acquisition More
- More on UniQure, in ‘Symbolic’ Win, Seeking
UK Approval of Huntington’s Gene Therapy More
- More on Verastem Launching 'Reimagine'
Campaign to Move Ovarian Cancer Drugs Into
Earlier Lines More
- Subscribe to LifeSci Startup for
Updates on US Startups More
- What We Heard at a Health Tech Conference in
Boston More*
|
|
 |
| Life
Sciences Talent and Consulting
Strategist George Quinn Named
Partner, Fractional Talent at
Slone Partners |
|
Learn More
→ |
|
|
- AI in Biotech: The New Frontier for
Leadership & Strategy More
- CollectiveMinds: Places Keith
Meadors as Chief Commercial Officer at Genova
Diagnostics More
- Empowering Students Through STEM: A
Conversation With Massachusetts Science &
Engineering Fair Executive Director Helen
Rosenfeld More
- From Seed to Series C: What
Investors Look for Beyond the Science More
- M&A in Life Sciences: The Turning Tide –
Why Now is a Strategic Inflection for
Biopharma and Biotech More
- More Than Executive Search: Building
Leadership for Every Stage of Growth More
- Pfizer’s Strategy Chief Andrew Baum Steps
Down; Helus Pharma Swaps Out CEO After Two
Months More*
- Telling Your Science Story to
Investors More
|
|
|
DISCOVER COMPANIES |
|
Big4Bio: Boston Life Science
Company Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
 |
|
|
|
 |
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:Boston,
all rights reserved 2026
© 2026
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|
